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Abstract 
During galenic formulation development, homogeneity of distribution is a critical parameter 
to check since it may influence activity and safety of the drug. Raman hyperspectral imaging 
is a technique of choice for assessing the distributional homogeneity of compounds of 
interest. Indeed, the combination of both spectroscopic and spatial information provides a 
detailed knowledge of chemical composition and component distribution. 
Actually, most authors assess homogeneity using parameters of the histogram of intensities 
(e.g. mean, skewness and kurtosis). However, this approach does not take into account spatial 
information and loses the main advantage of imaging. To overcome this limitation, we 
propose a new criterion: Distributional Homogeneity Index (DHI). DHI has been tested on 
simulated maps and formulation development samples. The distribution maps of the samples 
were obtained without validated calibration model since different formulations were under 
investigation. The results obtained showed a linear relationship between content uniformity 
values and DHI values of distribution maps. Therefore, DHI methodology appears to be a 
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suitable tool for the analysis of homogeneity of distribution maps even without calibration 
during formulation development. 
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1. Introduction 
 
During pharmaceutical development, assessment of the homogeneity of powder blends is a 
critical step that will impact both medicine safety and efficacy. Actually, HPLC is the 
commonly used technique consuming time and requiring a lot of resources. This is the reason 
why NIR and Raman spectroscopies have been more and more used to study powder blend 
processes [1-3]. However, none of these techniques can determine the spatial distribution of 
the components in the final product.  
 
Hyperspectral imaging combines spectral and spatial information. Therefore, it has gained in 
importance in pharmaceutical analysis during the last decade. Indeed, it allows obtaining 
simultaneously the API (Active Pharmaceutical Ingredient) concentration and its 
corresponding distribution map [4].  
In the pharmaceutical field, hyperspectral techniques are mainly based on Raman, near-
infrared (NIR-CI) or mid-infrared (MIR-CI) spectroscopies and have been used to obtain 
quantitative distribution maps of pharmaceutical ingredients [5-7], to detect and quantify 
polymorphs [8, 9], to characterize particle size [10], to detect counterfeit medicines [11] and 
to characterize blending conditions [12, 13]. 
 
Several approaches have been used to assess the distributional homogeneity in an objective 
way. Most of them used a quantitative model to obtain distribution maps and then analyzed 
the histogram of pixel concentrations [14-17]. Histograms parameters (mean, standard 
deviation, skewness and kurtosis) are useful to assess the “constitutional homogeneity” which 
is the dispersion of pixel concentration values [6]. However, two maps may have exactly the 
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same constitutional homogeneity while being spatially totally different. This is why it is also 
important to assess the distributional homogeneity. 
Usually, distributional homogeneity is assessed by visual inspection of distribution maps. 
This approach clearly lacks objectivity and if the difference between the two maps is tight, it 
is impossible to unequivocally declare which one is the most homogeneous.  
Therefore, Rosas et al. [18-20] developed a criterion to obtain an objective value of 
distributional homogeneity. This criterion is based on the analysis of the Poole index of non-
overlapping macropixels. However, this approach has several limitations. As it works with 
non-overlapping macropixels, it is quickly limited for the analysis of small distribution maps. 
Furthermore, studied map must be binarized. This binarization step is inevitably a source of 
error. Therefore, it appears that it could be advantageous to develop a new criterion which 
could analyze small maps and which would need as few input and pre-processing as possible 
to avoid as much error as possible. 
 
In this paper, we describe a new criterion called Distributional Homogeneity Index (DHI). 
This index can be performed on small maps with continuous values. Relevance of the 
developed DHI has been tested on simulated distribution maps of controlled increasing 
homogeneity. 
Secondly, DHI has been applied on several developed formulations with different content 
uniformity values. As these formulations were under investigation, no quantitative model (e.g. 
partial least square model) should be built. DHI was then tested on distribution maps obtained 
by semi-quantitative methods. 
 
2. Material and methods 
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2.1. Samples 
Several pilot blends of 8 kg were produced with different blending conditions, API particle 
size and excipients grade. Final concentration of API was of 8.4 % (w/w). These blends were 
then pressed in tablets of 80 mg and of 5 mm of diameter. 
 
Tablets were collected in a stratified way (begin, middle and end of the tableting) for several 
blends. For each blend, begin, middle and end samples were considered as different batches. 
Batch selection for hyperspectral analysis was performed choosing a specific blend and a 
specific tableting time. To do so, ten tablets per batch were randomly chosen, assayed by 
HPLC and the content uniformity (expressed as relative standard deviation, RSD %) and the 
European Pharmacopoeia’s acceptance value [21] were calculated.  
Batches with different content uniformity and acceptance values ranging from 0.46 % to 
11.04 % and from 1.10 to 29.41 respectively were selected. Once the batch selected, ten other 
tablets were randomly chosen and analyzed by hyperspectral Raman imaging.  
 
For confidentiality reasons, neither HPLC method nor information of tablet’s qualitative 
composition and blending conditions can be presented. Tablet’s quantitative composition is 
presented in supplementary Table S1. Spectral similarities between tablet’s components are 
presented as correlation coefficient values in supplementary Table S2.  
 
2.2. Instrumentation 
Raman hyperspectral images were collected with a dispersive Raman spectrometer 
RamanStation 400F (Perkin Elmer, MA, USA) equipped with a two-dimensional CCD 
detector (1024 × 256 pixel sensor). The laser excitation wavelength used was 785 nm with a 
power of 100 mW.  
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The measured spectral region was 1622-90 cm
-1
 and the spectral resolution was equal to 2 
cm
−1
. One accumulation with a 1 second exposure time was performed per sample mapping 
point. The distance between 2 consecutives mapping measurements was fixed at 100 µm. 
Background acquisition during mapping was repeated each 20 minutes. The spectra were 
collected with the Spectrum 6.3.2.0151 (Perkin Elmer) software.  
 
The analyzed tablet surface was prepared beforehand with a Leica EM Rapid milling system 
equipped with a tungsten carbide miller (Leica Microsystems GmbH, Wetzlar, Germany). 
 
Tablets were circular with a diameter of 6 mm (area of 28 mm²). Measured maps represented 
the greatest square possible with a map size of 40x40 and a step size of 100 µm. A total 
surface of 16 mm² was covered. 
Ten tablets per batch were analyzed. 
 
2.3. Data processing 
Once acquired, the hyperspectral images underwent preprocessing and multivariate analysis 
to extract useful information.  
First, hyperspectral data cubes (𝑀 ×𝑁 × 𝜆) were unfolded into a two-dimensional array 
(𝑀𝑁 × 𝜆) where 𝑀 and 𝑁 are the spatial information and λ the spectral information. Once 
unfolded, Raman spectra were baseline corrected using the Asymmetric Least Squares (AsLS) 
algorithm [22] with a λ value of 105 and a p value of 0.001. 
Then, cosmic rays have been removed using the algorithm developed by Sabin et al. [23] with 
a parameter k set at 15. 
 
Two multivariate data analysis approaches were used: 
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Classical Least Squares (CLS) regression: Distribution maps were obtained using CLS 
regression. This method assumes that Beer–Lambert’s law is respected and that the sum of the 
individual absorbance for each component equals the total absorbance for each pixel. 
Therefore, it computes the concentration of each component by direct regression of the 
hyperspectral data cube by using the pure spectra. 
It is a very easy and fast method but it is not flexible at all and any variability not reflected in 
the pure spectrum may affect the results [24]. Therefore, to obtain pure spectra as 
representative as possible, they have been resolved with Multivariate Curve Resolution – 
Alternating Least Squares (MCR-ALS). 
All analyzed maps were assembled and one every tenth spectrum was retained. Then, 
resolution of the pure spectra of each component was performed by the MCR-ALS toolbox 
[25-27]. Initial spectra estimates were obtained by simple-to-use-interactive self-modelling 
mixture analysis (SIMPLISMA) [28]. The constraints applied in the resolution analysis were 
non-negativity in the concentration profiles and spectra. 
The advantage of image multiset analysis by MCR-ALS is the higher robustness of the 
resolved spectra and concentration maps.  
Refolded CLS scores of the API were then used as distribution map. 
 
Principal Component Analysis (PCA): PCA is a variable reduction technique, which reduces 
the number of variables by making linear combinations of the original variables. These 
combinations are called the principal components (PC) and are defined in such way that they 
explain the highest (remaining) variability in the data and are by definition orthogonal. 
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The importance of the original variables in the definition of a principal component is 
represented by its loadings and the projections of the objects onto the principal components 
are called the scores of the objects [29].  
Unfolded preprocessed data cubes were mean centered before PCA analysis. The first PC was 
linked to the API with a good confidence since the correlation coefficient between the first 
loading and the pure API spectrum is higher than 0.966 (see supplementary Table S3). 
However, such a strategy is only applicable if a sufficient proof of correlation between the 
loading and the studied compound is obtained. Refolded scores of the first PC were then used 
as distribution map of the API. 
 
DHI and preprocessing of hyperspectral data cubes were performed using routines written in 
Matlab R2013a (The Mathworks, Natick, MA, USA). Multivariate data analysis was 
performed using the PLS_Toolbox 7.0.3 (Wenatchee, WA, USA) running on Matlab and 
MCR-ALS was performed using the toolbox described in [27].  
Analysis of experimental data was performed on Microsoft Excel 2010 (Microsoft, 
Albuquerque, NM, USA). 
 
3. Results and discussion 
 
3.1. Distributional Homogeneity Index (DHI) 
As stated before, conventional homogeneity testing of distribution maps consists of analyzing 
the histogram of pixel intensities. However, this technique is highly dependent on the spatial 
resolution of the hyperspectral imaging technique. Furthermore, this approach cannot 
differentiate two distribution maps with different spatial distribution if they have the same 
pixel intensities. 
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Therefore, a subsampling technique is necessary to evaluate the spatial homogeneity of a 
distribution map. This technique called macropixel analysis was first introduced by Hamad et 
al. [30]. A macropixel is a “square cluster of neighboring pixels with an intensity value equal 
to the average value of the included pixels”. Macropixel size can vary from a single pixel size 
to the entire distribution map size.  
The distribution map is first sampled by all possible macropixel of size 2x2 original pixel 
size. Then, all macropixels of size 3x3 are evaluated. The computation goes on with unit 
macropixel size increase until macropixel size equals the whole distribution map size. This 
approach is called the Continuous-Level Moving Block (CLMB) [30]. Therefore, for a 
defined macropixel size, there exists a total number of macropixels of (image size – 
macropixel size +1)². 
For each macropixel size, the standard deviation of the macropixel value is computed. Then, 
standard deviation is plotted against the macropixel size to obtain the so-called “homogeneity 
curve” [31]. 
Once the homogeneity curve obtained for the studied distribution map, the map is randomized 
and the homogeneity curve of the random map is computed. DHI value is obtained by the 
ratio of the area under the homogeneity curve (AUC) of the studied map and the area under 
the homogeneity curve of the randomized map (Figure 1). 
Because of the randomization step, many simulations are necessary (generally 50 to 100 
simulations) to compute a mean DHI value assorted with a standard deviation value. 
It is now obvious that DHI is rather an inhomogeneity index than a homogeneity index as its 
value increases as the homogeneity of the distribution map decreases. 
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Figure 1: Methodology to compute the Distributional Homogeneity Index (DHI). 
 
3.2. Test of DHI with controlled homogeneity maps 
In order to test the properties of DHI and to evaluate the relationship between DHI and 
distribution map homogeneity, controlled homogeneity maps were constructed. These maps 
were composed of 50 % pseudorandom values from the standard uniform distribution on the 
open interval (0, 1). The other half is composed of zeros.  
Therefore, a map of 10 % of controlled homogeneity means that a half of the image is 
composed of a random mix of 95 % of pseudorandom values and 5 % of zeros and the other 
half is composed of 95 % of zeros and 5 % of pseudorandom values. Doing so, one has an 
image with a total randomization of 10 % of the values keeping 90 % of the values divided in 
each half.  
Indeed, a 100 % controlled homogeneity map means that each half has 50 % of zeros and 50 
% of pseudorandom values randomly mixed. 
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Such simulated maps mimic well distribution maps and allow testing DHI on continuous 
values maps. Indeed, in the method developed by Rosas et al. [18-20], distribution maps are 
binarized prior to homogeneity evaluation. However, the threshold selection to achieve this 
binarization remains a non-trivial task and can therefore greatly affect the homogeneity 
measured. It appeared to us that the opportunity to work with continuous values maps could 
greatly ease the analysis. 
Controlled homogeneity maps of different sizes were built with homogeneity ranging from 90 
% to 10 %. Extreme homogeneity situations of 0 % and 100 % were avoided due to their 
unreal character that could mislead us in our conclusions. These maps were simulated four 
times and the DHI were computed. 
As one can see on Figure 2b, a direct linear relationship is found between DHI values and 
controlled homogeneity with coefficient of determination (R²) values higher than 0.99. 
Another important observation is that DHI values and best fit lines are different for each map 
size. Therefore, if one wants to compare two formulations, the analysis must be performed 
with the same parameters and the same map size. 
 
DHI has also been tested on 60x60 simulated maps with an varying proportion of lines of 
zeros and of lines of random values: 10/50, 20/40, 30/30, 40/20 and 50/10, respectively. 
Figure 3b shows the corresponding DHI values plotted against controlled homogeneity. As 
expected, simulated maps with equal proportion of random values and zeros have the higher 
DHI denoting the lowest homogeneity. Simulated maps with a higher proportion of zeros 
have higher DHI considering their opposite with a higher proportion of random values. This 
can be explained by the fact that DHI is based on the ratio of the AUC of the studied map and 
the AUC of the randomized studied map. Therefore, simulated maps with a higher proportion 
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of random values are more similar to the randomized map than their opposite and appear 
slightly more homogeneous (smaller DHI). 
 
This reinforces the fact that DHI must be performed only to check the homogeneity of a 
defined formulation. If one wants to compare many formulations with different API 
concentrations, preliminary tests are needed to confirm pertinence of future results. 
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a. 
 
b. 
 
Figure 2: a) Simulated distribution maps of size 100x100 with a proportion zeros and 
continuous values of 1:1. Extreme simulated maps (0 and 100 % of controlled homogeneity) are 
shown for illustration but were not analyzed by DHI. 
  b) Plot showing the relationship between DHI values and the controlled homogeneity 
of the simulated distribution maps of size 40x40 (red circles), 60x60 (blue triangles), 100x100 (green 
diamond-shaped), 140x140 (turquoise crosses) and 160x160 (violet squares). Each controlled 
homogeneity map has been simulated four times. Best fit linear relationship was drawn with the four 
computed DHI values. Equation and coefficient of determination of corresponding best fit lines are 
shown. 
 14 
a. 
 
b. 
 
Figure 3: a) Simulated distribution maps of size 60x60 with a growing proportion of zeros. For 
better visualization, only the maps of 0 % controlled homogeneity are shown. 
  b) Plot showing the relationship between DHI values and the controlled homogeneity 
of the simulated distribution maps of size 60x60. Different proportions of zeros and continuous values 
of respectively 10/50 (red circles), 20/40 (blue triangles), 30/30 (green diamond-shaped), 40/20 
(turquoise crosses) and 50/10 (violet squares) were analyzed. Each controlled homogeneity map has 
been simulated three times. Best fit linear relationship was drawn with the four computed DHI values. 
Equation and coefficient of determination of corresponding best fit lines are shown. 
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3.3. Analysis of real samples 
As DHI represents spatial heterogeneity in API distribution, it has been decided to validate it 
with the well-known content uniformity test. The main idea was to develop a non-destructive 
and ecological friendly test that could be used by pharmaceutical industry while developing 
new formulations. Once prepared (milled), tablet are not destroyed by hyperspectral imaging 
and could therefore stay in a sample bank for further analysis or even inspections. 
During formulation development, five batches of tablets were produced with content 
uniformity ranging from 0.46 % to 11.04 %. These batches represent well the variability that 
can be encountered during formulation development: different API particle size, excipient 
grades and blending conditions. 
Once obtained, the hyperspectral images were processed and the distribution maps were 
obtained by CLS or PCA analysis (see section 2.3). DHI were computed on distribution maps 
obtained by the two methods. 
Figure 4 shows the obtained content uniformity values plotted against the measured DHI 
values. As can be seen, a linear relationship (R² close to 0.99) is observed between DHI and 
content uniformity values validating the DHI methodology with real pharmaceutical samples. 
Another interesting observation is that DHI values measured from distribution maps obtained 
by both CLS and PCA are comparable (Table 1).  
These observations constitute a major advantage of the DHI methodology since it is now 
possible to determine which formulation is the more homogeneous with neither any 
calibration dataset nor wet chemistry step. Indeed, multivariate calibration is difficult to 
implement since it necessitates the production of calibration samples with different nominal 
concentrations. Furthermore, any change in formulation leads to a complete re-development 
of the calibration model which is clearly not possible during formulation development step. 
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Hyperspectral imaging enables a fast analysis of different formulations while keeping 
prepared samples in a sample bank for any further analysis. 
 
Table 1: Acceptance values, content uniformity and mean DHI values computed on distribution maps 
obtained by both CLS and PCA for the five developed formulations (batches A-E).  
 
Similarly, the calculated European Pharmacopoeia’s acceptance values were plotted against 
the measured DHI values (Figure 5). Once again, a clear linear relationship is observed. It 
could therefore be possible to predict whether a formulation will have an acceptance value 
below the threshold of 15 or not with a defined uncertainty. 
 
Based on DHI analysis of the distribution maps of the different formulations, formulation A 
was selected as the best formulation. Indeed, choosing this formulation ensures us that the 
formulation has the lowest content uniformity value and that its acceptance value is below the 
threshold value of 15. 
 
Coefficients of determination with real samples are lower than those obtained with simulated 
images. This can be explained by sampling errors with real samples. Indeed, Raman 
hyperspectral imaging only analyzes the surface of the sample whereas content uniformity 
Batch Reference Acceptance Value 
Content 
Uniformity(n=10) 
(RSD %) 
Mean DHI Value 
computed on CLS 
distribution maps 
(n=10) ± Standard 
Error 
Mean DHI Value 
computed on PCA 
distribution maps 
(n=10) ± Standard 
Error 
A 1.10 0.46 2.066 ± 0.110 2.080 ± 0.114 
B 4.54 1.60 2.333 ± 0.077 2.345 ± 0.071 
C 8.64 3.56 2.445 ± 0.103 2.434 ± 0.104 
D 23.31 8.29 3.051 ± 0.151 3.080 ± 0.154 
E 29.41 11.04 3.491 ± 0.194 3.470 ± 0.196 
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values obtained by HPLC analyzes the whole tablet. Furthermore, only ten tablets per batch 
were tested (as recommended by the European Pharmacopoeia) but it is not really 
representative of a batch of about 100 000 tablets. Another parameter that must be optimized 
is the laser spot size and the spatial resolution of the hyperspectral analysis which are 
dependent on the particle size of the different present components. 
 
All these sampling issues are under investigation to develop a generic approach that could be 
set up for any kind of homogeneity determination. 
 
a.       b. 
       
Figure 4: a) Plot showing the relationship between the content uniformity values (RSD %) and 
the computed DHI values. DHI were computed with the distribution maps obtained by CLS analysis of 
the hyperspectral images of the tablet samples (see section 2). Each point represents the mean DHI 
value of ten tablets assorted with the corresponding standard error. 
  b) Plot showing the relationship between the content uniformity values (RSD %) and 
the computed DHI values. DHI were computed with the distribution maps obtained by PCA analysis of 
the hyperspectral images of the tablet samples (see section 2). Each point represents the mean DHI 
value of ten tablets assorted with the corresponding standard error. 
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a.      b. 
     
Figure 5: a) Plot showing the relationship between the European Pharmacopoeia’s acceptance 
values and the computed DHI values. DHI were computed with the distribution maps obtained by CLS 
analysis of the hyperspectral images of the tablet samples (see section 2). Each point represents the 
mean DHI value of ten tablets assorted with the corresponding standard error. Red dotted line 
represents the maximal authorized acceptance value of 15. 
  b) Plot showing the relationship between the European Pharmacopoeia’s acceptance 
values and the computed DHI values. DHI were computed with the distribution maps obtained by PCA 
analysis of the hyperspectral images of the tablet samples (see section 2). Each point represents the 
mean DHI value of ten tablets assorted with the corresponding standard error. Red dotted line 
represents the maximal authorized acceptance value of 15. 
 
Conclusion 
 
A new methodology for the assessment of spatial homogeneity in hyperspectral images has 
been presented. This methodology called Distributional Homogeneity Index (DHI) is based 
on the ratio of the area under the curve of the homogeneity curve of the raw studied map and 
the area under the curve of the homogeneity curve of the randomized studied map. 
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The DHI have been tested on simulated maps of increasing controlled homogeneity 
mimicking distribution maps of the studied compound. A linear relationship has been found 
between DHI values and controlled homogeneity. It has also been demonstrated that DHI 
values were dependent of map size. Therefore, to be compared, two tablets must be analyzed 
with the same parameters.  
Simulated maps of the same size but with different proportions of zeros were tested. DHI 
values were, as presumed, dependent of the proportion of zeros. Therefore, two blend 
mixtures with very different proportions of the studied compound must be compared 
cautiously. 
Nevertheless, it has been shown that DHI is a useful methodology to compare the distribution 
homogeneity of different blend mixtures during formulation development. This comparison is 
possible with distribution maps obtained without any calibration by CLS or PCA which 
lightens substantially the analysis work and enables a fast and non-destructive analysis of the 
samples. 
The DHI approach has been tested on real samples of different pilot batches during 
formulation development. Linear relationship has been observed between DHI values and 
content uniformity values and with European Pharmacopoeia’s acceptance values of the 
different batches allowing the selection of the most homogeneous formulation. 
 
As with any application of hyperspectral imaging, sampling aspects are very important. This 
is why laser spot size, the spatial resolution and the achievement of a representative sampling 
of the studied batches are currently under investigation. The final objective is the elucidation 
of parameters to be optimized for the development of a generic approach of homogeneity 
assessment with hyperspectral imaging. 
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